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ABSTRACT
Objectives: Newer oral allergic rhinitis (AR) medica-
tions, the second-generation antihistamines (SGAs) have
gained widespread acceptance because of their efﬁcacy
and reduced side effects relative to ﬁrst-generation anti-
histamines (FGAs). There are no empirical studies com-
paring the costs of treatment of SGAs relative to FGAs.
Methods: We analyzed data from a 20% beneﬁciary sam-
ple (approximately 120,000 continuously enrolled bene-
ﬁciaries per year) for the Medi-Cal Fee-for-Service
program during 1999 to 2000. AR medications available
under Medi-Cal included three SGA medications (lorata-
dine, fexofenadine, and cetirizine) and over 200 FGA
products containing either diphenhydramine or chlorphe-
niramine or both. Because multiple medications were
evaluated, a sample selection model was estimated using a
two-stage multinomial logistic—variance components
regression framework.
Results: SGA medications have signiﬁcantly lower total
direct health-care treatment costs per patient than FGA
medications with costs ranging from $347 to $448 less
(P < 0.001), despite higher AR medication costs. Total
drug expenditures were also not signiﬁcantly different for
patients using SGA or FGA medications despite SGA pre-
scriptions averaging $47 higher than FGAs. Emergency
department visits, inpatient admissions and physician
ofﬁce visits were also signiﬁcantly lower for patients using
SGA medications.
Conclusions: Signiﬁcant cost and utilization reductions
were associated with all of the SGA medications relative
to FGA drugs, despite their higher acquisition costs. If
facing higher copayments for prescription AR drugs,
many patients, particularly lower income patients, may
choose cheaper over-the-counter (OTC) FGAs rather than
SGAs. Our analysis ﬁnds this might lead to increased
overall health-care treatment costs, unless Medicaid and
health insurance plans subsidize OTC AR medications.
Keywords: allergy, costs, Medicaid, multinomial logit,
oral antihistamines, sample selection bias.
Introduction
Allergic rhinitis (AR) impacts more than 40 million
Americans annually. Estimates of the annual direct
and indirect economic burden of AR illness exceed
$8 billion in 2000 US dollars [1–8]. The cost of AR
medications alone has been estimated to exceed $6
billion annually [5]. Workforce productivity losses
constitute a substantial component of AR costs of
illness, ranging from 10 to 60% of the total costs
per patient in various studies [9–12].
Newer generation oral AR medications, the sec-
ond-generation antihistamines (SGAs) have gained
widespread acceptance because of their efﬁcacy,
minimal sedation, and reduced side effects relative
to ﬁrst-generation antihistamines (FGAs) such as
diphenhydramine (e.g., Benadryl®) and chlorphe-
niramine (e.g., Chor-Trimeton®). These SGAs
include loratadine (Claritin®), fexofenadine (Alle-
gra®), cetirizine (Zyrtec®) and desloratadine (Clar-
inex®). Evidence-based literature reviews have
found that nasal steroids are more effective and less
costly than nonsedating antihistamines in the treat-
ment of AR [1,4,5]. Nevertheless, nasal steroids are
less convenient than oral medications for many
patients. Although SGAs are more expensive than
FGAs, the reduced rate of sedation and other med-
ication symptoms with SGAs may improve patient
functioning and reduce other AR patient health-
care requirements and costs relative to FGAs
[13,14]. Two recent studies have modeled the cost
effectiveness of SGAs relative to FGAs [15,16]. In
these studies Sullivan et al. found that switching
patients from FGAs to SGAs could save $100 ($64–
137) per AR sufferer, as well as provide substantial
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increases in quality-adjusted life-years to the AR
patient population. Nevertheless, reduced prescrip-
tion coverage for SGA medications could impact
AR treatment costs and patient outcomes. Sullivan
and Nichol noted that “… some of the drug savings
from limiting coverage of prescription SGA may be
attenuated by the cost of lost productivity and
direct medical expenditures due to unintentional
injuries associated with increased FGA use in
addition to the increased cost of therapeutic
substitutes.” [16] There are no empirical studies
comparing either the costs of treatment, or cost
effectiveness of SGAs relative to FGAs, and only a
few studies comparing treatment costs among dif-
ferent SGAs [17,18].
The recent availability of loratadine (Claritin®)
in the nonprescription over-the-counter (OTC)
market raises the question of whether AR patient
health-care costs will increase or decrease as AR
patients switch, or are switched to, OTC oral
medications. Many health insurance and Medicaid
plans do not reimburse for medications that are
available OTC. Others require higher copayments
or additional paperwork to obtain insurance cover-
age for prescriptions in that therapeutic class [19].
It is well established that prescription drug con-
sumption is highly sensitive to price and insurance
coverage [20–23]. Based on a study of Medicare
recipients, Stuart and Grana report that low-income
elderly without supplemental drug insurance cover-
age are 40% less likely to use prescription medi-
cations than higher income (>$18,000 annual
income) elderly with supplemental drug coverage
[24]. They also found that the odds ratio for use of
prescription medications to treat cold and allergies
was  (1.83:  95%  CI  1.24–2.69)  among  elderly
with drug insurance coverage compared to those
without.
Given this result, if drug beneﬁt insurance
coverage for SGAs is reduced or eliminated, the
nonsedating  antihistamines  Rx-to-OTC  switch
will increase consumer net price and reduce SGA
demand. This, in turn, will increase demand for the
cheaper FGA OTC medications, such as diphenhy-
dramine and chlorpheniramine, particularly among
those AR patients with low income and/or high out-
of-pocket medical expenses.
Although OTC antihistamines unquestionably
reduce drug expenditures for third party payers rel-
ative to covered prescription products, there are no
published studies evaluating the effects of alterna-
tive oral antihistamines on overall patient health-
care costs. This study evaluates health-care resource
use among patients taking different oral antihista-
mines to determine the effects of alternative oral AR
medications on total health-care costs, after adjust-
ing for patient treatment characteristics and treat-
ment selection bias.
Methods
To examine the potential effects of the likely chang-
ing utilization patterns for oral antihistamines on
patient health-care costs, we used data from a 20%
beneﬁciary sample, approximately 120,000 contin-
uously enrolled beneﬁciaries per year, for those
California counties participating in the Medi-Cal
Fee-for-Service program during the period from
1998 to 2000 when SGAs were initially introduced
[25]. We focused on the three SGA medications
(loratadine, fexofenadine, and cetirizine) available
under Medi-Cal, and over 200 FGA products
containing either diphenhydramine or chlorphe-
niramine or both.
The use of Medi-Cal claims history data for the
period before OTC SGA availability has several
advantages over other databases to assess these
issues. Since the availability of OTC loratadine, it is
very difﬁcult to determine which AR medications
patients are actually taking because OTC medica-
tions are seldom captured in insurance claims re-
cords. Moreover, because Medi-Cal covers generic
FGA products as well as SGA products, patient
usage of all AR medications is well-captured in the
claims history. Finally, because Medi-Cal patients
face no copayment differences between generic and
brand name medications, they faced no ﬁnancial
incentives to use one category of AR medications
rather than another. This substantially reduces the
amount of potential selection bias between medica-
tions in evaluating patient’s treatment costs and use
of medical services.
Because SGAs were not approved on the Medi-
Cal formulary until 1998, and were not all widely
utilized by Medi-Cal patients until 1999, the data
were restricted to the time frame from 1999 to
2000. Because total health-care costs are not
observed for those patients with interrupted eligi-
bility, the sample was restricted to those beneﬁciar-
ies with continuous eligibility in each year with at
least one prescription for SGA or FGA medications
(45,810 patients in 1999; 46,970 patients in 2000).
Because of the seasonal nature of allergy illness
[26], health-care costs during every year of contin-
uous eligibility were included in the analysis for any
patients with one or more years of continuous eli-
gibility. Repeated observations were available on
roughly half of the patient sample, allowing panel
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data variance components econometric estimation
methods to be used.
Not all antihistamine use is for AR, although the
vast majority of antihistamine users are diagnosed
with AR. Because of the unreliable outpatient diag-
nostic indicators in claims history databases our
analysis focuses on patients with any use of antihis-
tamines, adjusting for comorbid diagnoses, rather
than attempting to rely on outpatient diagnostic
codes to determine which patients have AR. It
should be noted that there are concerns about AR
diagnostic accuracy itself. According to Szeinbach
et al.[27]:
Only 35.4% of the patients who used an oral
antihistamine and were diagnosed with an
allergy tested positive to the multiallergen-
speciﬁc IgE test, and only 38% of the patients
with records of frequent antihistamine use and
who were diagnosed as allergic tested positive to
the multiallergen-speciﬁc IgE test. Apparently,
there are patients taking medications prescribed
for allergic rhinitis who are, in fact, not allergic,
which is both wasteful economically and not
indicated medically.
The Medi-Cal claims history billing records have
limited medical history and diagnostic information.
To evaluate the relative impact on treatment costs of
SGA and FGA medications we measured the incre-
mental impact on total health-care costs per patient
for each of these medications, rather than attempt-
ing to construct AR-speciﬁc treatment costs based
on the unreliable diagnostic information in the
claims data. We have included a number of diag-
nostic indicators for patient comorbidities that are
likely to involve inpatient treatment, and thus be
more costly and more reliable in terms of diagnostic
coding in the claims data. Restricting the sample to
those with deﬁnitive AR diagnosis would over-
weight patients with inpatient admissions, which
could lead to spurious cost estimates. We excluded
3% of antihistamine patients for whom the index
antihistamine was something other than FGA or
SGA medications. There were no other demo-
graphic or patient history exclusion criteria.
Drugs were identiﬁed by NDC codes. Category
of services is provided in the Medi-Cal data diction-
ary. Comorbidities were identiﬁed through ICD-9
coding, mostly for inpatient claims, but also for out-
patient claims where available. All of the data ele-
ments are described in [25]. All costs were adjusted
to 2000 US dollars using the medical care compo-
nent of the Consumer Price Index (CPI) provided by
US Bureau of Labor Statistics (http://www.bls.gov).
Because they reﬂect the actual transactions, contrac-
tual amounts reimbursed by Medi-Cal were used to
calculate treatment costs, rather than provider bill-
ing amounts. Medi-Cal receives substantial conﬁ-
dential discounts from published or list prices for all
types of medical services, particularly drugs. By fed-
eral law Medi-Cal (Medicaid) receives the lowest
nationally available price for all prescription medi-
cations. Long-term care costs were excluded from
the analysis.
Although Medi-Cal patients face minimal and
identical copayments regardless of medication
choice, it is well-known that medication treatment
selection can be nonrandom, reﬂecting both patient
and provider characteristics and propensities [28–
30]. To further complicate empirical analysis,
patients can discontinue prescription medications,
or switch from one medication to another during an
AR treatment episode for a variety of reasons
including patient-perceived lack of treatment efﬁ-
cacy, medication side effects, convenience, provider
and/or patient detailing, etc. To adjust for both
observable and unobservable cofactors explaining
differences in treatment we developed a sample
selection model of treatment choice using repeated
observations on many of the patients in a variance-
components panel data framework to adjust for any
patient-speciﬁc and provider-speciﬁc characteristics
impacting treatment costs [31,32].
Because multiple medications were available, the
standard binary choice sample selection model
framework was expanded to a multinomial choice
framework with four treatment choices: loratadine,
fexofenadine, cetirizine or FGA using the method-
ology developed by Lee and described by Maddala
[31,33]. The sample selection model is based on a
two-stage multinomial logistic variance compo-
nents regression framework. In the ﬁrst stage, med-
ication treatment choice is estimated as a function
of patient characteristics using a multinomial logis-
tic probability estimator. Then selection bias coefﬁ-
cients, lij are calculated for each medication choice
i and patient j using the formula:
lij = j(F-1(Fi(zijy)))/Fi(zijy) (1)
where j(.),F(.) represent the standard normal prob-
ability density and distribution functions, respec-
tively; Fi(zijy) is the multinomial logistic probability
of treatment choice i, given observable patient char-
acteristics zij and estimated logistic probability
parameters y. Because of the independence of irrel-
evant alternatives structure of the multinomial
logistic estimation model, lij will be invariant to the
number of alternative medication choices [31].
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The second-stage variance components regres-
sion estimator for health-care costs is:
Hij = dij[Xj b + hi + alij + uij] (2)
where Hij is total annual health-care costs for
patient j using medication i, dij is an indicator vari-
able that equals 1 if patient j is observed to choose
medication i and is zero otherwise, Xj is a vector of
observable characteristics explaining annual health-
care costs, hi is the incremental effect of medication
i on treatment costs, and a is the estimated coefﬁ-
cient on the sample selection bias coefﬁcient vector
lij.  uij  is  the  linear  regression  error  term.  uij  will
be heteroskedastic for several reasons. First, using
estimated values for lij creates heteroskedastic
errors [29]. Second given the small number of avail-
able explanatory factors in the data set, there are
potential individual-speciﬁc omitted explanatory
variables.
The advantage of a ﬁxed effects variance compo-
nents model is that any omitted characteristics that
are patient-speciﬁc can be adjusted for in the esti-
mation procedure as part of the patient-speciﬁc
error component (e.g., patient medical history, prior
treatment costs, preference for treatment, sociode-
mographics, etc.). Because the Medi-Cal claims data
have only a very limited set of demographic (age,
sex, race/ethnicity) and comorbidity measures
(ICD-9 codes from the claims records) to use as
explanatory factors, it is important to utilize this
capability of panel data estimation to adjust for
potential confounders that we are unable to capture
in the data.
Given the repeated annual observations on many
patients in the sample, a random effects model for
the regression error terms would be feasible if
omitted unobservable explanatory factors were not
correlated with the observable explanatory charac-
teristics [32]. Because this is not a plausible assump-
tion for these data, we chose a ﬁxed-effects error
speciﬁcation for the patient-speciﬁc variance com-
ponents. Rather than explicitly characterizing the
error covariance structure, we used an SPSS 12.0
macro to adjust the linear regression parameter esti-
mates in Equation 2 for generalized heteroskedas-
ticity (http://www.spss.com) [34].
In addition to looking at total medical costs, we
looked at speciﬁc categories of medical expendi-
tures per AR patient, including: emergency depart-
ment expenditures, drug expenditures, outpatient
expenditures, inpatient expenditures and other
medical care expenditures. The same sample selec-
tion estimation model and correction for variance
components (Equations 1–2) and same sets of
explanatory variables were used in each of the
expenditure subcategory analyses.
As further validation of the estimates, we used
ordinal regressions on subcategories of medical
service utilization counts to determine whether the
pattern of medical utilization for emergency care
visits, inpatient care, and physician ofﬁce visits was
similar to that found for medical expenditure cate-
gories. For this analysis ordinal regression methods
are superior to count models, such as the Poisson
regression or the negative binomial regression meth-
ods, because of the required rigid relationship
between mean and variance in count models, and
the requirement that utilization differences preserve
cardinality. Ordinal regression methods merely
require that “more services” reﬂect higher service
intensity without imposing cardinality of service
counts. Because medical utilization and service vis-
its differ substantially in time, complexity and cost,
it is inappropriate to use cardinal counts for them.
Moreover, even if cardinality is empirically correct,
the ordinal regression models will generate unbi-
ased estimates. Both the ordinal link logit and ordi-
nal link probit models were estimated, and the ﬁrst-
stage selection bias correction factors were included
in the ordinal regressions to adjust for nonrandom
AR drug treatment selection.
Results
Medical Cost and Service Utilization Differences for 
Patients Using Different AR Medications
Table 1 provides the descriptive characteristics for
the sample population. The patients were 38%
male, 10% African Americans, 12% Hispanic, and
42% other nonwhite. Total annual health-care
expenditures (excluding long-term care costs) per
patient averaged $3800, with drug expenditures
(both AR and all other medications) averaging more
than half of total health-care expenditures.
As shown in Table 2, only 16% of the patient
sample used more than one AR medication type,
and essentially all of these multiple medication
patients used only two medications. In the ﬁrst anal-
ysis we restrict attention to the 84% of patients
with only one medication type. We then extended
the results to include patients with multiple
medications.
Table 3 shows the ﬁrst-stage multinomial logistic
estimates for the sample. The estimates use a ﬁxed
effects error component estimation approach to
account for additional unobservable patient-level
characteristics. Most of the covariates are highly
signiﬁcant, with males, African Americans, and
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younger patients more likely to use FGA medica-
tions, whereas other nonwhite ethnic groups were
less likely than whites or Hispanics to use FGA.
Fexofenadine, loratadine, and cetirizine were all
more likely to be used in 2000 than FGA medica-
tions. Existing comorbidities are highly signiﬁcant
in predicting AR medication choice. The Table 3
multinomial logit results are used primarily to gen-
erate the selection bias coefﬁcients for the second-
stage cost regressions and ordinal utilization count
regressions. As such the coefﬁcient estimates do not
have direct policy signiﬁcance. Nevertheless, the
ﬁnding that speciﬁc observable characteristics are
signiﬁcantly related to medication choice indicates
that a correction for selection bias needs to be con-
sidered in this case.
Table 4 provides the variance components regres-
sion results adjusting for treatment selection bias.
FGA is the omitted (default) treatment choice cate-
gory. It can be seen that all of the SGA medications
have signiﬁcantly lower total health-care treatment
costs per patient than FGA medications with total
Table 1 Patient descriptive characteristics
Descriptive statistics
1999 2000 
N Mean SD N Mean SD
Total health-care spending (adjusted by medical CPI) 45,810 3,737 8,398.66 46,970 4,055 9,016.08
FGA medication spending 45,810 6.43 18.57 46,970 5.31 15.19
SGA medication spending 45,810 86.59 139.45 46,970 115.39 168.32
Sex (1 = Male) 45,810 38.9% 0.49 46,970 37.7% 0.48
African American 45,810 9.8% 0.30 46,970 9.7% 0.30
Hispanic 45,810 12.8% 0.33 46,970 11.1% 0.31
Other non-white 45,810 41.4% 0.49 46,970 42.5% 0.49
Age squared 45,810 3,168.04 2,471.77 46,970 3,777.54 23,208.44
Age 45,810 49.77 26.28 46,970 50.87 25.58
Asthma prescriptions ﬁlled 42,725 0.31 0.46 43,751 0.33 0.47
Diagnosis of COPD 42,725 5.3% 0.22 43,751 5.3% 0.22
Diagnosis of congestive heart failure 42,725 3.9% 0.19 43,751 3.5% 0.18
Diagnosis of hyperlipidemia 42,725 6.1% 0.24 43,751 6.6% 0.25
Diagnosis of hypertension 42,725 19.2% 0.39 43,751 19.2% 0.39
Diagnosis of stroke 42,725 5.5% 0.23 43,751 4.6% 0.21
Diagnosis of cardiovascular disease 42,725 47.7% 0.50 43,751 51.5% 0.50
Diagnosis of emphysema 42,725 0.5% 0.07 43,751 0.5% 0.07
Diagnosis of diabetes 42,725 11.5% 0.32 43,751 12.1% 0.33
Diabetes prescriptions ﬁlled 42,725 13.4% 0.34 43,751 14.4% 0.35
Diagnosis of cancer 42,725 2.0% 0.14 43,751 2.0% 0.14
Diagnosis of sinusitis 42,725 8.7% 0.28 43,751 7.9% 0.27
Drug expenditures 45,810 1,975 3,837.02 45,790 2,294 3,841.65
Outpatient expenditures 30,821 596 3,863.36 29,319 637 4,769.24
Long-term care expenditures 1,133 514 4,796.92 1,131 432 4,590.30
Inpatient expenditures 1,938 176 2,770.03 2,125 166 2,748.66
Other medical care expenditures 14,835 477 53.55 13,865 524 56.70
COPD, chronic obstructive pulmonary disease.
Table 2 Allergic rhinitis medication use
(A) Number of different medications used
Number of antihistamine medications used: 1999–2000
No. Frequency Percent
1 77,729 83.8
2 13,089 14.1
3 1,826 2.0
4 136 0.1
Total 92,780 100.0
(B) Medication cost* and frequency of use
Number and percentage of patients using various AR medications
1999 2000
Prescription cost ($) Frequency Percent Frequency Percent
Fexofenadine 229 5,497 12 6,984 15
Cetirizine 202 6,363 14 8,727 19
Loratadine 178 16,290 36 18,478 39
First-generation antihistamines 26 19,891 43 16,233 35
*Prescription costs exclude conﬁdential rebates to the Medi-Cal program.
Medi-Cal Treatment Costs with Oral Antihistamines 511
paid medical costs ranging from $347-$448 less
than with FGA (P < 0.001), despite the higher AR
medication costs. Expenditure differences among
the three SGA medications were not signiﬁcant.
Because all exogenous variables are included in
both the ﬁrst- and the second-stage estimation equa-
tions, the model is identiﬁed through nonlinearities
in the Mills ratio selection terms. Although this can
raise issues of multicollinearity, examination of the
collinearity diagnostics showed that the variance
inﬂation factors are mostly less than 2, and always
less than 20. Given the high levels of signiﬁcance
and large patient sample size, multicollinearity is
not a problem for these estimates.
As expected, treatment costs increase with age
and year of observation. Health-care costs were sig-
niﬁcantly greater for African Americans and lower
for Hispanics and other ethnic groups (white was
the omitted race/ethnicity category). Indicators of
either diagnosis or medication use for comorbidities
were all highly signiﬁcant. Since the ﬁxed effects
variance components model adjusts for other unob-
servable patient-speciﬁc characteristics including
medical history, additional comorbidities and
patient and provider medication preferences, the
results are robust. To determine whether these
results also hold for AR patients on multiple medi-
cation types, the selection model on total health-
care costs was re-estimated using a ﬁve-choice
logistic probability framework, with multiple med-
ications representing an additional ﬁfth treatment
choice category. Treatment costs for FGA medica-
tions were signiﬁcantly higher than the three SGA
medications as a group (P < 0.05), although the
pairwise difference between FGA and each separate
SGA treatment cost did not reach statistical signif-
icance (results available from authors on request).
The fact that all of the Table 4 selection bias
coefﬁcients (lambdas) were signiﬁcant indicates that
unobservable factors were signiﬁcantly correlated
Table 3 Multinomial logistic parameter estimation of medication choice*
N = 92,780
Choice of AR medication
Parameter estimates† 
FGA Fexofenadine Cetirizine Loratadine
Intercept 665.36 -217.24 -441.1 -61.193
(0.00) (0.00) (0.00) (0.15)
Sex 0.148 -0.03 0.106 0.015
(0.00) (0.35) (0.00) (0.51)
African American 0.245 -0.119 -0.153 -0.035
(0.00) (0.05) (0.01) (0.42)
Hispanic -0.007 -0.223 -0.131 -0.242
(0.86) (0.00) (0.02) (0.00)
Other race -0.375 -0.603 -0.464 -0.489
(0.00) (0.00) (0.00) (0.00)
Age -0.043 0.042 -0.029 -0.031
(0.00) (0.00) (0.00) (0.00)
Year -0.332 0.108 0.221 0.031
(0.00) (0.00) (0.00) (0.15)
Asthma medication -0.648 -0.381 -0.397 -0.304
(0.00) (0.00) (0.00) (0.00)
COPD diagnosis 0.309 0.112 -0.011 0.075
(0.00) (0.08) (0.87) (0.13)
CHF diagnosis 0.312 0.063 0.042 0.023
(0.00) (0.42) (0.58) (0.70)
Lipid diagnosis -0.163 -0.009 0.01 0.006
(0.00) (0.88) (0.85) (0.89)
Hypertension diagnosis 0.057 -0.098 -0.05 -0.048
(0.04) (0.01) (0.19) (0.10)
Stroke diagnosis 0.103 0.113 0.079 0.025
(0.03) (0.08) (0.21) (0.62)
CVD medication -0.178 -0.086 -0.091 -0.149
(0.00) (0.02) (0.02) (0.00)
Emphysema diagnosis 0.145 -0.218 -0.083 -0.067
(0.28) (0.27) (0.67) (0.64)
Diabetes diagnosis 0.004 -0.114 -0.08 -0.043
(0.93) (0.06) (0.17) (0.34)
Diabetes medication 0.123 0.099 0.132 0.068
(0.00) (0.08) (0.02) (0.11)
Cancer diagnosis -0.039 -0.164 -0.033 -0.091
(0.58) (0.11) (0.73) (0.22)
Sinusitis diagnosis -1.101 -0.344 -0.509 -0.284
(0.00) (0.00) (0.00) (0.00)
*Fixed-effects error component parameter estimates are omitted because of space limitations.
†P-value for the null hypothesis in parentheses below each coefﬁcient estimate.
CVD, cardiovascular disease.
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with both the choice of AR medications and the
costs associated with AR treatment. In fact, when
the lambdas were excluded from the model estima-
tion, the results were still signiﬁcant, but the mag-
nitude of the cost savings associated with SGA
medications were only about half of what was esti-
mated in the Table 4 results (results available from
authors on request). On the other hand, when we
estimated the model using ordinary least squares
(ignoring patient-speciﬁc unobservables and heter-
oskedasticity) the results were very similar to the
Table 4 results. This implies that correcting for
selection bias is important for these data, but cor-
recting for heteroskedasticity is not.
To determine which speciﬁc medical service costs
decrease with use of SGA medications, the selection
bias correction model was rerun on medical cost
subcategories. Table 5 provides the cost parameter
estimates for each SGA medication (relative to
FGA) for drug expenditures, inpatient costs, outpa-
tient costs, and other medical service costs (which
include durable medical equipment, home health,
lab and diagnostic tests, etc.). It can be seen that the
reductions in inpatient, outpatient, and other med-
ical service costs are signiﬁcant for patients using
SGA drugs. Furthermore, drug expenditures are not
signiﬁcantly different for patients using SGA and
FGA medications despite the fact that FGA medi-
cations averaged $3 per prescription and SGA
medications averaged $50 per prescription. The
increases in AR medication costs were offset by
reductions in other medication expenditures for
SGA patients, particularly emergency department
costs and other medical costs.
In addition to medical costs, we also looked at
speciﬁc categories of medical service utilization
using ordinal regression to evaluate service counts.
Table 6 demonstrates that the same pattern
observed with costs was seen with signiﬁcantly
higher medical service utilization (emergency
department admissions, inpatient admissions, and
physician ofﬁce visits) for patients using FGA med-
ications relative to those using SGA medications
(P < 0.01), using ordinal logit link function regres-
sion after adjusting for the same demographic and
comorbidity covariates shown in Table 4. As a fur-
ther sensitivity analysis check, we also re-estimated
the cost regressions as two-part models using log-
transformed costs in the second equations and
found predicted cost differences similar to those
reported in Tables 4 and 5 [35].
Finally, we brieﬂy examined the pattern of med-
ication switching among patients initiating any of
the FGA or SGA medications during the two year
Table 4 Total health-care costs variance components regression dependent variable: total health-care spending (adjusted by
medical CPI)
Parameter Estimate
Parameter 
signiﬁcance
95% CI 
Lower bound Upper bound
Intercept -601,848 0.00 -819,738 -38,3957
Sex 578.44 0.00 429.69 727.19
African American 550.11 0.00 287.45 812.78
Hispanic -1902.23 0.00 -2137.49 -1666.96
Other race -657.11 0.00 -826.85 -487.38
Age squared 0.04 0.00 0.03 0.05
Age -34.84 0.00 -40.60 -29.08
Year 304.33 0.00 195.61 413.05
Asthma medication 923.69 0.00 778.91 1068.48
COPD diagnosis 2583.71 0.00 2316.52 2850.89
CHF diagnosis 2898.99 0.00 2596.48 3201.50
Lipid diagnosis 575.36 0.00 343.12 807.60
Hypertension diagnosis 820.52 0.00 662.48 978.56
Stroke diagnosis 1954.21 0.00 1700.49 2207.93
CVD medication 1408.45 0.00 1244.52 1572.38
Emphysema diagnosis 2474.91 0.00 1698.74 3251.07
Diabetes diagnosis 1767.80 0.00 1532.78 2002.81
Diabetes medication 655.18 0.00 411.38 898.98
Cancer diagnosis 2186.38 0.00 1802.91 2569.84
Sinusitis diagnosis 405.19 0.00 138.26 672.12
Fexofenadine -346.80 0.00 -568.68 -124.91
Cetirizine -447.97 0.00 -649.21 -246.73
Loratadine -378.04 0.00 -523.96 -232.11
Mlambda A* 1546.57 0.00 1180.75 1912.39
Mlambda Z* 371.65 0.02 57.99 685.31
Mlambda C* -303.55 0.09 -658.20 51.10
Mlambda F* 227.60 0.00 122.60 332.59
*Multinomial selection bias correction factor: A, fexofenadine; Z, cetirizine; C, loratadine; F, ﬁrst-generation antihistamine.
CHF, congestive heart failure.
N = 92,780.
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period. As shown in Table 7, those patients who
switched medications were more likely to switch to
an SGA medication than to an FGA medication.
These results were also found in multinomial logit
regressions, adjusting for patient demographics and
comorbidities.*
Discussion
There is substantial evidence that FGA medication
increases AR patient injury and accident rates
primarily because of high levels of sedation [16,36–
39]. This is the ﬁrst evaluation of health-care treat-
Table 5 Medical service component cost differences for SGA relative to FGA medications*
Parameter Estimate
Parameter 
signiﬁcance†
95% CI 
Lower bound Upper bound
Drug costs n = 91,600
Fexofenadine -63.47 0.21 -162.78 35.83
Cetirizine 3.33 0.942 -86.8 93.45
Loratadine -42.72 0.193 -107.1 21.66
Inpatient costs n = 4,063
Fexofenadine -25.73 0.252 -69.73 18.28
Cetirizine -41.99 0.04 -82.01 -1.98
Loratadine -41.57 0.009 -72.94 -10.19
Outpatient costs n = 60,140
Fexofenadine -17.94 0.517 -72.27 36.39
Cetirizine -45.23 0.079 -95.67 5.21
Loratadine -49.18 0.017 -89.57 -8.79
Emergency department costs n = 17,421
Fexofenadine -29.75 0.000 -42.92 -16.57
Cetirizine -17.92 0.002 -29.14 -6.71
Loratadine -32.87 0.000 -41.60 -24.15
Other medical costs n = 28,700
Fexofenadine -115.66 0.007 -200.36 -30.96
Cetirizine -78.32 0.048 -155.91 -0.73
Loratadine -76.95 0.011 -136.51 -17.39
*Regression results shown are adjusted for the same covariates and selection bias factors shown in Table 4.
†Parameter signiﬁcance reﬂects the t test type-I probability for each SGA that cost category values are different from FGA treatment costs.
Table 6 Medical service utilization differences for antihistamine medications
Parameter Estimate
Parameter 
signiﬁcance
95% CI 
Lower bound Upper bound
Emergency department visits n = 17,421
FGA medications 0.21 0.00 0.14 0.28
Fexofenadine -0.09 0.09 -0.20 0.02
Cetirizine -0.15 0.00 -0.25 -0.05
Loratadine -0.24 0.00 -0.32 -0.17
Inpatient admissions n = 4,063
FGA medications 0.36 0.00 0.27 0.45
Fexofenadine -0.06 0.38 -0.19 0.07
Cetirizine -0.05 0.48 -0.17 0.08
Loratadine 0.02 0.72 -0.08 0.12
Physician ofﬁce visits n = 3,043
FGA medications 0.46 0.00 0.25 0.674
Fexofenadine 0.15 0.34 -0.16 0.461
Cetirizine -0.27 0.12 -0.60 0.069
Loratadine -0.09 0.48 -0.34 0.16
Logit link ordinal regression results adjusted for the same covariates shown in Table 4.
Table 7 Antihistamine medications switching patterns
Switched to drug in class Frequency Percent
No. switch 63,420 68.36
Switched to
First-generation antihistamines (FGA)
Chlorphenhydramine 2,402 2.59
Diphenhydramine 3,564 3.84
Second-generation antihistamines (SGA)
Cetirizine 2,929 3.16
Fexofenadine 2,862 3.08
Loratadine 6,943 7.48
Other medications
Nasal steroid 7,928 8.54
Other AR medication 2,732 2.94
Total 92,780 100.00
*Additional results tables are available online at http://
www.ispor.org/valueinhealth_index.asp.
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ment costs for AR patients comparing SGA and
FGA medications, adjusting for treatment selection
bias, demographics, comorbidities, and unobser-
vable patient-speciﬁc variance components. The
analysis ﬁnds signiﬁcant AR treatment cost and uti-
lization reduction associated with each of the SGA
medications relative to FGA drugs, despite their
higher acquisition costs. Inpatient and outpatient
costs trend lower with all SGA medications. Signif-
icant cost reductions are observed for emergency
and other medical services, whereas total drug
expenditures per AR patient are not signiﬁcantly
higher for those taking SGA medications. The
results are robust, and are observed in regressions
evaluating utilization of several types of medical
services directly, as well as speciﬁc medical service
cost component regressions.
Because all of the costs are estimated using Medi-
Cal prices, the estimated cost differences are pro-
jected to be substantially larger among private
sector health insurers and MCOs. Moreover, Medi-
Cal receives additional conﬁdential rebates from
SGA manufacturers that make the SGA cost-savings
even larger than our estimates, which are based on
publicly available drug prices.
Medi-Cal (Medicaid) patients are low-income
and from a relatively lower socioeconomic status
compared to typical US AR patients and managed
care enrollees. The Medi-Cal AR population is
bimodal, with many young beneﬁciaries covered
under the AFDC and S-CHP programs, and many
older beneﬁciaries being jointly eligible for Medi-
care. Generalizability of these ﬁndings beyond the
Medi-Cal or Medicaid populations should be done
with caution. Nevertheless, it should be pointed out
that because Medi-Cal covers prescriptions even
when equivalent OTC products are available, none
of the Medi-Cal AR patients had to choose therapy
based on differences in AR medication costs. This
means that the observed medical cost differences in
this study are even less pronounced than would be
observed in an AR patient population which had
self-selected FGA medications because of out-of-
pocket differences in medication costs. When the
analyses were separately repeated for older
(Medicare-eligible) and younger Medi-Cal-only AR
patients, the same signiﬁcant medical cost differ-
ences obtained between AR patients choosing FGA
and SGA medications still obtained, implying that
patient age and type of Medi-Cal eligibility did not
explain the cost difference results.
Ideally, one would like to measure the actual
impact of making SGA medications available OTC,
rather than using data from the pre-OTC switch
era. Nevertheless, it is empirically impossible (or
very difﬁcult) to evaluate the impact of this policy
change in a post-OTC world, precisely because
OTC medications are not tracked in third party
claims data. It is difﬁcult to know which OTC
medications AR patient are taking, including Medi-
Cal patients, because they are not reimbursed for
OTC medications. Therefore, the cleanest way to
compare the costs associated with FGA and SGA
medications is using data from the immediate pre-
OTC era.
Health insurers have successfully convinced
drug manufacturers to move at least one SGA
medication (loratadine) to OTC status. One moti-
vation is to reduce health plan covered expendi-
tures on AR medications by encouraging greater
use of noncovered nonprescription AR medica-
tions. Nevertheless, evaluation of Medi-Cal claims
data suggest that such a strategy could lead to
higher health plan payments if patients substituted
cheaper FGA OTC medications for more expen-
sive SGA medications. With higher copayments for
SGA drugs, many patients, particularly lower
income patients, may choose cheaper OTC FGA
medications rather than loratadine or other rela-
tively expensive SGA medications. Although it is
likely that the price differential between OTC
diphenhydramine and OTC loratadine will dimin-
ish over time, OTC loratadine will likely never
become as cheap as OTC FGA products. Current
prices for OTC FGAs can be found on the internet
for less than $0.02 per pill.
Our analysis ﬁnds that FGA usage may increase
annual treatment costs from $347 to $448 per AR
patient. Sullivan and Nichol’s AR medication cost
effectiveness modeling implies that careful structur-
ing of health plan and Medicaid AR medication
beneﬁts to subsidize OTC SGAs could overcome
these problems by preventing large-scale switches to
OTC FGA products, without net increases in health
plan expenditures [16]. Certainly OTC availability
of SGA products will improve access to nonsedating
AR medications for those who would not otherwise
visit a physician and obtain an SGA prescription.
But eliminating coverage for OTC loratadine and
restricting access to other SGAs may result in
increased medical expenditures as a result of inap-
propriate use of substitute drugs or discontinuation
of drug therapy [19].
This analysis has the typical limitations of retro-
spective data analysis. Although we have attempted
to adjust carefully for selection bias, heteroskedas-
ticity, and other estimation issues, and found our
results to be quite robust to various alternative spec-
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iﬁcations, omitted variables or model speciﬁcation
errors may have impacted our ﬁndings.
It is unclear whether medication compliance,
additional inpatient and outpatient visits to deal
with AR disease, medication symptoms, comorbid-
ities or other factors result in higher treatment costs
for FGA patients relative to SGA patients. There is
evidence that optimal management of AR will
decrease ER and inpatient utilization for comorbid-
ities such as asthma [36]. The ﬁnding that patients
switching medications were more likely to switch to
an SGA medication than to an FGA medication sug-
gests a preference for the newer SGA medications.
Additional research with more detailed medical his-
tory information not available in claims history
data is needed to determine which speciﬁc medical
history and medication treatment patterns contrib-
ute to the observed increase in medical care costs for
patients taking FGA medications.
Source of ﬁnancial support: Research supported by an
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